Eli Lilly $LLY moved deeper into neuroscience with a definitive agreement to acquire AtaiBeckley $ATAI for $6.75 a share in cash, or about $2.8B of upfront equity value. The company release also adds a contingent value right of up to $2.50 a share, representing about $1.0B of additional potential equity value if specified development and regulatory milestones are met.

The deal is above the finance crawler’s $500M M&A threshold and has a direct listed-equity catalyst. Lilly said the upfront price represents about a 40% premium to AtaiBeckley’s 30-day volume-weighted average trading price through July 15, 2026. The CVR milestones include $1.00 a share for starting a Phase 3 trial of VLS-01 before the fourth anniversary of closing, $0.50 for U.S. approval and DEA rescheduling of BPL-003 before the fifth anniversary, and $1.00 for U.S. approval and DEA rescheduling of VLS-01 before the seventh anniversary.

The strategic asset is BPL-003, an intranasal synthetic form of 5-MeO-DMT for treatment-resistant depression. Lilly said BPL-003 has Breakthrough Therapy Designation from the FDA and has initiated Phase 3 activities. AtaiBeckley’s second program, VLS-01, is a DMT buccal film in an ongoing Phase 2b study. The acquisition gives Lilly a faster route into psychedelic-derived psychiatry while the company’s diabetes and obesity franchises fund larger pipeline expansion.

The closing target is the third quarter of 2026, subject to AtaiBeckley shareholder approval, regulatory approvals and customary conditions. The next watch items are the proxy filing, antitrust review and whether the CVR milestones become investable reference points for $ATAI holders before the deal closes.

Not investment advice. Verify all figures with primary sources before acting.

#atai

Lilly $LLY buys AtaiBeckley $ATAI for $2.8B upfront; CVR adds $1.0B